Tanja Obradovic: Novel cell therapy is entering clinical development space
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“Novel cell therapy is entering clinical development space and is aiming to tackle solid tumors. FDA just cleared today IND of very innovative CLD201.
CLD201 (or SuperNova-1) product is a Vaccinia virus CAL1-loaded allogeneic mesenchymal stem cells. CLD201 is designed for intratumoral administration and based on information from ASCO 2024 and announcement today tumors targeted in the Phase I may be head and neck squamous cell carcinoma (HNSCC), triple negative breast cancer (TNBC) and advanced soft tissue sarcoma.
Many questions remain on what exactly development path in the clinical phase of CLD201 may be as likely hurdles are many and cell therapy for solid tumors remains challenging. It is intriguing that melanoma is not one of indications considering that intratumoral injections of combination with systemic PD(L)1 inhibitor has a proven concept of activity. Phase I trial of CDL201 is not posted yet so definitively of interest to follow in the future.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023